Compare BTBT & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTBT | KMDA |
|---|---|---|
| Founded | 2015 | 1990 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 569.7M | 458.6M |
| IPO Year | 2017 | 2013 |
| Metric | BTBT | KMDA |
|---|---|---|
| Price | $1.62 | $8.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $7.00 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 19.4M | 74.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 2.30% |
| EPS Growth | ★ 218.75 | N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $108,050,720.00 | N/A |
| Revenue This Year | $7.15 | $14.04 |
| Revenue Next Year | $90.95 | $7.99 |
| P/E Ratio | ★ $3.52 | $24.59 |
| Revenue Growth | ★ 140.56 | N/A |
| 52 Week Low | $1.49 | $5.54 |
| 52 Week High | $4.55 | $9.35 |
| Indicator | BTBT | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 42.04 | 49.84 |
| Support Level | $1.53 | $6.69 |
| Resistance Level | $2.43 | $8.88 |
| Average True Range (ATR) | 0.11 | 0.28 |
| MACD | 0.01 | -0.08 |
| Stochastic Oscillator | 10.94 | 31.87 |
Bit Digital Inc is engaged in the Bitcoin mining business, Ethereum staking activities and specialized cloud-infrastructure services for artificial intelligence applications through its wholly owned subsidiaries. Its mining platform operates with the primary intent of accumulating bitcoin which may sell for fiat currency from time to time depending on market conditions. The Company has four reportable segments: digital asset mining, cloud services, colocation services, and ETH Staking. It generates majority of its revenue from digital asset mining.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.